A case of high-risk AML in a patient with advanced systemic mastocytosis

Abstract

Aggressive SM + AML has limited therapeutic options. Even a strong combination of decitabine-venetoclax-midostaurin has a transient effect on AML and a mitigated effect on SM. Larger series are required to identify the best therapeutic strategy.

Keywords: HAM regimen; advanced systemic mastocytosis (AdvSM); cladribine; concurrent hematologic disease; decitabine–venetoclax (DEC‐VEN); refractory acute myeloid leukemia (R‐AML).